Scarica l'app Stockscreener
15.19
1.68%
-0.26
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock - Investing.com UK
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com - Investing.com Nigeria
Form 4 Contineum Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options - Stock Titan
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice - MSN
Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,000 in shares By Investing.com - Investing.com South Africa
Price to sales forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Contineum Therapeutics CEO Stengone sells $40,000 in shares - Investing.com
Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan - Stock Titan
Form 144 Contineum Therapeutics For: 8 July By Investing.com - Investing.com South Africa
CTNM insider selling 2,500 shares via option exercise; prior 10,000-share 10b5-1 sale - Stock Titan
Price to earnings forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - AOL.com
Enterprise value to revenue forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Price to book forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Enterprise value to EBIT forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Continued Clinical ProgressEstimate Uncertainty - dars.gov.et
Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock By Investing.com - Investing.com South Africa
Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock - Investing.com
Contineum (NASDAQ: CTNM) CSO sells 37,179 shares and exercises 33,009 options - Stock Titan
Contineum Therapeutics CEO Stengone sells $160,080 in stock By Investing.com - Investing.com Australia
Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock - Investing.com UK
Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock By Investing.com - Investing.com Nigeria
Form 4 Contineum Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics (CTNM) Sees 9.2% Pre-Market Surge - GuruFocus
Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise - Stock Titan
Contineum Therapeutics CEO Stengone sells $160,080 in stock - Investing.com
[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Form 144 Contineum Therapeutics For: 1 July By Investing.com - Investing.com India
Insider sales and option exercise at CTNM (NASDAQ: CTNM) - Stock Titan
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - BioSpace
Form 144 Contineum Therapeutics For: 30 June By Investing.com - Investing.com Nigeria
Contineum publishes discovery data on LPAR1 antagonist PIPE-791 - Investing.com
CTNM (NASDAQ) notice to sell 28,826 shares; broker Morgan Stanley named - Stock Titan
[144] Contineum Therapeutics, Inc. SEC Filing - Stock Titan
Contineum publishes discovery data on LPAR1 antagonist PIPE-791 By Investing.com - Investing.com India
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to Russell 2000 Index - marketscreener.com
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to Russell 2000 Value Benchmark - marketscreener.com
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):